

A. Andújar¹, C. Matoses Chirivella¹, J.M. del Moral Sánchez¹, A. Martínez Valero¹, A. Martí Llorca¹, F.J. Rodríguez Lucena¹, A. Navarro Ruiz¹. ¹Hospital General Universitario de Elche, Pharmacy Department, Elche, Spain.

Objective:

To compare the prevalence of the pharmacotherapy treatment lines of inpatients prescribed by active ingredient (AI) against to the brand name (BN) medicines.

Study Design:

- **Type of study:** Observational and retrospective study in an university tertiary hospital conducted during October 2013.
- **Inclusion criteria:** Inpatients admitted at non-critical hospital units.
- **Method:** Pharmacists at the Unit of Dose Drugs Dispensing System (UDDDS) reviewed all the treatment lines of their medical orders.
- **Data source:** We designed a database to filled with the data collected: AI, TN, number of lines of treatment prescribed as an AI or BN, medical service and treatment group according to the WHO classification instituted "ATC" (Anatomical, Therapeutic, Chemical classification system).
- **The results obtained were compared with those observed in a similar study at October 2010.**


Results:

Main services prescribers by AI


2010 - Hematology

2013 - Short Stay Unit, Pediatrics and Neurosurgery

% prescriptions by AI



ATC classification 2013



Conclusion

Most medical orders continue being prescribed by the Brand Name despite the recommendations. Maybe, when computer-assisted prescription comes to our hospital, this situation will be reversed.